Work

Molecular Tumor Boards: Realizing Precision Oncology Therapy

Year: 2017

Type: article

Abstract: Technological advances in high-throughput next-generation sequencing (NGS) along with advances in computational processes have brought about the dawn of the genomic medicine era. NGS has enabled molecular characterization of malignancies, and facilitated the development and approval of gene- and immune-targeted therapies, both of which impact the mutanome. Clinical implementation of this technology, approval of novel targeted agents, and establishment of molecular tumor boards has enabled precision oncology to become a reality.

Source: Clinical Pharmacology & Therapeutics

DOI: 10.1002/cpt.920

Authors: Maulik Patel, Shumei M. Kato, Razelle Kurzrock

Institutions: University of California San Diego, Moores Cancer Center

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Pfizer, Actuate Therapeutics, Foundation Medicine, National Cancer Institute